DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Veltuzumab
Veltuzumab
Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
Wien, 28
Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix
New Biological Therapies: Introduction to the Basis of the Risk of Infection
(12) United States Patent (10) Patent No.: US 9,161,992 B2 Jefferies Et Al
Veltuzumab, an Anti-CD20 Mab for the Treatment of Non-Hodgkin's
2017 Immuno-Oncology Medicines in Development
One Target, Different Effects: a Comparison of Distinct Therapeutic Antibodies Against the Same Targets
Novel Designs of Multivalent Anti-CD20 Humanized Antibodies As Improved Lymphoma Therapeutics
Epratuzumab–SN-38: a New Antibody–Drug Conjugate for the Therapy of Hematologic Malignancies
(INN) for Biological and Biotechnological Substances
Current Immunotherapy Approaches in Non-Hodgkin Lymphomas
Therapy of Advanced B-Lymphoma Xenografts with a Combination of 90Y-Anti-CD22 Igg (Epratuzumab) and Unlabeled Anti-CD20 Igg (Veltuzumab) M
Impact of Obinutuzumab Alone and in Combination for Follicular Lymphoma
INN Working Document 05.179 Update 2011
Stembook 2018.Pdf
Monoclonal Antibody (Mab)-Based Biotherapy Options for B-Lineage
Immunoconjugates Advances in the Treatment of Hematologic
Top View
IUPAC Glossary of Terms Used in Immunotoxicology (IUPAC Recommendations 2012)*
2018 Medicines in Development for Cancer
Redalyc.Advances in the Diagnosis and Control of Lymphomas
(INN) for Biological and Biotechnological Substances
Antibody Drug Conjugates Still Making Slow Progress
Antibody-Based Immunotherapy Immunology Department Student Lecture April 11, 2006
CHMP Assessment Report
CD20-Targeted Therapy: a Breakthrough in the Treatment of Non-Hodgkin’S Lymphoma
Scientific Rationale for Immunotherapy in Lymphoma and Predictors of Response
A61K9/51 (2006.01) — with International Search Report (Art
Epidermal Growth Factor Receptor–Targeted Radioimmunotherapy of Human Head and Neck Cancer Xenografts Using 90Y-Labeled Fully Human Antibody Panitumumab
N° 18380 A61k 31/5377 (2018.01) A61p 35/02 (2018.01)
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
© Ferrata Storti Foundation
B-Cell Depletion in Immune Thrombocytopenia
Ibrutinib- Obinutuzumab Chlorambucil
Anticancer Medications and Sodium Dysmetabolism
Analyses of CD20 Monoclonal Antibody-Mediated Tumor Cell Killing Mechanisms: Rational Design of Dosing Strategies
(12) Patent Application Publication (10) Pub. No.: US 2017/0152480 A1 Jensen (43) Pub
1 1 RISK FACTORS an Investment in Genmab's Shares, Including Any New Shares, Involves a High Degree of Risk. in Addition to Th
New Anti-CD20 Monoclonals
(12) United States Patent (10) Patent No.: US 9.295,731 B2 Nguyen (45) Date of Patent: Mar
Biotechnology Presented by America’S Biopharmaceutical Research Companies
Diapositiva 1
Presentación De Powerpoint
Orphan Drug Designations and Approvals List As of 06‐01‐2015 Governs July 1, 2015 ‐ September 30, 2015
The Honorable Shara Aranoff Chairman United States International Trade Commission 500 E Street, S.W. Washington, DC 20436 Dear C
Anti-CD22/CD20 Bispecific Antibody with Enhanced Trogocytosis for Treatment of Lupus
Anti-CD22 90Y-Epratuzumab Tetraxetan
Qualifying Therapeutic Discovery Project Grants
Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
International Journal of Current Advanced Research
Impact of Obinutuzumab Alone and in Combination for Follicular Lymphoma
Oncology Drugs in the Pipeline
New Agents for the Treatment of Lymphoma
Cancer PRESENTEDBYAMERICA ’ SBIOPHARMACEUTICALRESEARCHCOMPANIES Nearly 900 Medicines and Vaccines in Testing Offer Hope in the Fight Against Cancer
(INN) for Biological and Biotechnological Substances
Emerging Treatment Options for Adolescents and Young Adults with Relapsed Or Refractory Lymphoma
Medicines & Vaccines in Development for Cancer
Qr2012 Q3 E02 En.Pdf
Assessment of the Evolution of Cancer Treatment Therapies
Oncology Drugs in the Pipeline
Radioimmunotherapy
Pretargeted Versus Directly Targeted Radioimmunotherapy Combined with Anti-CD20 Antibody Consolidation Therapy of Non-Hodgkin Lymphoma
INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri
(12) Patent Application Publication (10) Pub. No.: US 2015/0374790 A1 Liu Et Al